Radiopharm Theranostics Ltd (RADX) Common Equity (2023 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Common Equity of $274565.9 for Q2 2025, up 52.31% year-over-year from $180264.9 in Q2 2024, and up 52.31% quarter-over-quarter from $180264.9 in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Common Equity (2023 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Common Equity for 3 consecutive years, with $274565.9 the latest figure, recorded in Q2 2025.
- In Q2 2025, Common Equity rose 52.31% year-over-year to $274565.9; the TTM figure through Jun 2025 stood at $274565.9 (up 52.31% YoY), while the FY2025 annual figure was $42.9 million, up 56.73% from the prior year.
- Common Equity grew to $274565.9 in Q2 2025 per RADX's latest filing, from $180264.9 in the prior quarter.
- Across five years, Common Equity topped out at $45.6 million in Q2 2023 and bottomed at $180264.9 in Q2 2024.
- Historically, Common Equity has averaged $15.3 million across 3 years, with a median of $274565.9 in 2025.
- Annual changes were most pronounced in 2024 — Common Equity sank 99.6% — and 2025, when it jumped 52.31%.
- Radiopharm Theranostics' Common Equity stood at $45.6 million in 2023, then plunged by 99.6% to $180264.9 in 2024, then soared by 52.31% to $274565.9 in 2025.
- Business Quant data shows RADX's Common Equity at $274565.9 in Q2 2025, $180264.9 in Q2 2024, and $45.6 million in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 274,565.91 |
| Jun 30, 2024 | 180,264.85 |
| Jun 30, 2023 | 45.58 Mn |